Next, we utilized a VCaP castration-resistant prostate cancer model (VCaP-CRPC) for further assessment of CBPD-409 anti-tumor efficacy alone or in combination with the AR antagonist enzalutamide (Figure 8A). Here, AR is linked to prostate carcinoma.